Articles

Disruptions to pharmaceutical supply chains have been ever-present, causing challenging shortages on key medicines. Read More ›

Patient Empowerment Through Advocacy: Encourage Your Patients to Join Our Community of ANGELS for Support, Education, and Inspiration

By Maimah Karmo

Patient Advocacy

January 2025 Vol 18, No 1

Whether they are currently undergoing breast cancer treatment, supporting a loved one, or seeking to become a community ally, the Tigerlily Foundation’s ANGEL Advocacy Program can offer people comprehensive advocacy training, educational resources, and the support of a warm community. Read More ›

Maimah Karmo

Subgroup Analyses Continue to Support Investigational DLBCL Treatment

By Cara Guglielmon

ASH Highlights

January 2025 Vol 18, No 1

Subgroup analyses presented at the 66th American Society of Hematology Annual Meeting and Exposition in San Diego support the clinical benefit of brentuximab vedotin (Adcetris; Pfizer) in heavily pretreated patients with relapsed or refractory diffuse large B-cell lymphoma. Read More ›

Cara Guglielmon

Nurturing the Caregiver: Essential Tips for Combating Seasonal Affective Disorder

By Catherine S Bishop, DNP, NP, AOCNP

Practitioner Wellness

January 2025 Vol 18, No 1

As the days grow shorter and darker, it’s easy to fall prey to feelings of sadness and isolation, and although you cannot always avoid experiencing seasonal affective disorder, you can make lifestyle changes to manage it and prevent future episodes. Read More ›

Catherine S Bishop, DNP, NP, AOCNP

You Spoke and We Listened: The Oncology Pharmacist 2024 Reader Survey Results

Web Exclusives

Thank you to all of our TOP readers who gave us feedback on our December 2024 survey. Read More ›

WCLC 2024 HER2-Mutated NSCLC

Longer-Term Follow-Up of Amivantamab + Lazertinib vs Osimertinib From the MARIPOSA Study

Rapid Reactions

Videos

In the final video of this Rapid Reactions series, Beth Sandy, MSN, CRNP, FAPO, discusses data that continue to favor first-line amivantamab plus lazertinib over osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer after a median of 31 months of follow-up.

WCLC 2024 HER2-Mutated NSCLC

Zongertinib, a Novel HER2-Specific Tyrosine Kinase Inhibitor for HER2-Positive Solid Tumors with Brain Metastases

Rapid Reactions

Videos

In this video, Beth Sandy, MSN, CRNP, FAPO, discusses data showing that zongertinib demonstrated manageable safety and promising efficacy in patients with HER2 aberration-positive solid tumors, including those with baseline brain metastases.

WCLC 2024 HER2-Mutated NSCLC

HARMONi-2: Phase 3 Study of Ivonescimab vs Pembrolizumab in 1L Treatment for Patients with PD-L1-Positive Advanced NSCLC

Rapid Reactions

Videos

In this video, Beth Sandy, MSN, CRNP, FAPO, discusses ivonescimab, a bispecific antibody targeting PD-1 and VEGF that produced a tolerable safety profile and clinically significant improvement in efficacy compared with pembrolizumab.

WCLC 2024 HER2-Mutated NSCLC

Targeting HER2-Mutated NSCLC With Zongertinib

Rapid Reactions

Videos

Zongertinib, a HER2 TKI, demonstrated clinically meaningful activity and tolerability in patients with NSCLC with and without brain metastases harboring a HER2 mutation.

Quick Quiz: Lung Cancer Edition

Quick Quizzes

Lung cancer is the top cause of cancer death and the third most common cancer type in the United States, according to the National Cancer Institute. With an estimated 234,580 new cases of lung and bronchus cancer to be diagnosed in 2024 alone, this cancer will almost certainly affect a portion of your patients. Test your knowledge of this disease here. Read More ›

Articles

Page 3 of 288